Financial Performance - The company's operating revenue for Q1 2025 was CNY 1,673,699,598.01, a decrease of 6.95% compared to CNY 1,798,732,648.44 in the same period last year[4] - Net profit attributable to shareholders increased by 16.77% to CNY 78,597,649.89 from CNY 67,307,574.42 year-on-year[4] - The net profit after deducting non-recurring gains and losses was CNY 64,656,985.97, up 21.14% from CNY 53,371,705.45 in the same period last year[4] - Net profit for Q1 2025 increased to CNY 82,348,970.57, compared to CNY 70,966,706.12 in Q1 2024, representing a growth of 15.88%[18] - Total comprehensive income amounted to CNY 81,042,801.40, an increase from CNY 70,966,706.12 in the previous year, representing a growth of approximately 14.4%[19] Cash Flow - The net cash flow from operating activities decreased significantly by 83.50%, amounting to CNY 26,871,193.66 compared to CNY 162,849,287.26 in the previous year[4] - The net cash flow from operating activities for Q1 2025 was CNY 26,871,193.66, a significant decrease from CNY 162,849,287.26 in Q1 2024[22] - Cash inflow from operating activities totaled CNY 1,280,615,436.19, compared to CNY 1,322,433,200.60 in the same period last year, reflecting a decline of about 3.2%[22] - Cash outflow from operating activities was CNY 1,253,744,242.53, up from CNY 1,159,583,913.34, indicating an increase of approximately 8.1%[22] - The net cash flow from financing activities was negative CNY 4,003,435.49, an improvement from negative CNY 58,395,522.27 in the previous year[23] - The company experienced a cash outflow of CNY 605,003,435.49 from financing activities, compared to CNY 328,516,673.91 in Q1 2024, indicating an increase of about 84.2%[23] - The cash flow from investment activities was negative CNY 68,002,277.49, an improvement from negative CNY 94,536,998.13 in the same period last year[22] Assets and Liabilities - Total assets at the end of the reporting period were CNY 9,135,906,979.71, reflecting a slight increase of 0.42% from CNY 9,097,984,876.42 at the end of the previous year[5] - The company's total assets amounted to CNY 9,135,906,979.71, an increase from CNY 9,097,984,876.42 in the previous period[14] - Current liabilities totaled CNY 3,259,579,625.77, up from CNY 3,060,932,068.62, indicating an increase of 6.49%[14] - Non-current liabilities decreased to CNY 1,733,613,899.56 from CNY 1,975,482,433.06, a reduction of 12.26%[15] - The company's total equity rose to CNY 4,142,713,454.38, compared to CNY 4,061,570,374.74, marking an increase of 2.00%[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 127,650[9] - The largest shareholder, Hualu Holding Group Co., Ltd., holds 20.6% of the shares, totaling 185,896,620 shares[9] Expenses - Total operating costs for Q1 2025 were CNY 1,603,575,969.64, down from CNY 1,738,362,575.97 in Q1 2024, reflecting a reduction of 7.73%[17] - Research and development expenses for Q1 2025 were CNY 68,836,886.27, down from CNY 80,658,203.12 in Q1 2024, a decrease of 14.66%[18] - The company reported a decrease in sales expenses to CNY 117,380,480.29 from CNY 201,910,852.00, a significant reduction of 41.76%[18] Earnings Per Share - The company reported a basic and diluted earnings per share of CNY 0.09, compared to CNY 0.08 in the previous year, marking a 12.5% increase[19] Government Subsidies - The company received government subsidies amounting to CNY 14,796,766.41, which are closely related to its normal business operations[6] Product Development - The company did not report any significant new product developments or market expansion strategies during this quarter[11]
鲁抗医药(600789) - 2025 Q1 - 季度财报